Investing in Stocks Made Easy!
at ₹0 Brokerage with 5paisa.
+91
By proceeding, you agree to all T&C*
Investing in Stocks Made Easy!
We've sent a 6-digit verification code to +91 99123918232
Didn't receive the code? Resend
CURIS

Curis Lifesciences Share Price

 

 

Curis Lifesciences live price: ₹124. It opened at ₹126 vs previous close ₹124; intraday high/low: ₹126/₹124. The 50 DMA stands at ₹115.81.

Curis Lifesciences Performance

  • Today's Low
  • ₹124
  • Today's High
  • ₹126
  • 52 Week Low
  • ₹84
  • 52 Week High
  • ₹148
  • Open Price₹126
  • Previous Close₹124
  • Volume2,000
  • 50 DMA₹115.81
  • 100 DMA₹116.12
  • 200 DMA-

Curis Lifesciences Chart

Investment Returns

  • Over 1 Month + 10.71%
  • Over 3 Month + 25.25%
  • Over 6 Month -9.82%
  • Over 1 Year -3.12%

Smart Investing Starts Here Start SIP with Curis Lifesciences for Steady Growth!

Invest Now

Curis Lifesciences Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 16.4
  • PEG Ratio
  • -
  • Market Cap Cr
  • 100
  • P/B Ratio
  • 4.7
  • Average True Range
  • 4.97
  • EPS
  • 7.55
  • Dividend Yield
  • 0
  • MACD Signal
  • 5.63
  • RSI
  • 54.58
  • MFI
  • 75.46

Latest Stock News Updates

Curis Lifesciences Acquires Majority Stake in Uninova, Accelerates Multi-Continent Expansion

.

Curis Lifesciences Financials

Curis Lifesciences Technicals

EMA & SMA

Current Price
₹124.00
+ 0.5 (0.4%)
pointer
  • Bearish Moving Average 6
  • Bullish Moving Average 7
  • 20 Day
  • ₹122.79
  • 50 Day
  • ₹115.81
  • 100 Day
  • ₹116.12
  • 200 Day
  • -

Resistance and Support

124.62 Pivot Speed
  • R3 127.08
  • R2 126.47
  • R1 125.23
  • S1 123.38
  • S2 122.77
  • S3 121.53

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Curis Lifesciences manufactures pharmaceutical products with a specialization in ophthalmic sterile ointments. The company focuses on producing high-quality, compliant formulations for healthcare needs, supported by dedicated manufacturing capabilities and a growing presence in the domestic pharmaceutical market.

Curis Lifesciences Ltd has an operating revenue of Rs. 148.05 Cr. on a trailing 12-month basis. An annual revenue growth of 38% is outstanding, Pre-tax margin of 17% is great, ROE of 37% is exceptional. The company has a reasonable debt to equity of 46%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 13% and 8% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around -7% from the pivot point (which is the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 95 which is a GREAT score indicating consistency in earnings, a RS Rating of 69 which is FAIR indicating the recent price performance, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 29 indicates it belongs to a strong industry group of Medical-Ethical Drugs and a Master Score of C is fair but needs to improve. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Curis Lifesciences Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-12-04 Quarterly Results

Curis Lifesciences Shareholding Pattern

68.03%
0%
1.19%
0.06%
14.38%
16.34%

Curis Lifesciences FAQs

Curis Lifesciences share price is ₹124 As on 23 May, 2026 | 00:59

The Market Cap of Curis Lifesciences is ₹100.2 Cr As on 23 May, 2026 | 00:59

The P/E ratio of Curis Lifesciences is 16.4 As on 23 May, 2026 | 00:59

The PB ratio of Curis Lifesciences is 4.7 As on 23 May, 2026 | 00:59

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23